Mark A Quinn

6.8k citations

97 papers · 5.5k · 2 hit papers · h-index 32

Impact in

Rheumatology top 0.1%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Musculoskeletal synovial abnormalities and treatments
- Spondyloarthritis Studies and Treatments
Hematology top 2%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 37
- Rheumatoid Arthritis Research and Therapies 33
- Systemic Lupus Erythematosus Research 14
Insect Science 15
- Insect-Plant Interactions and Control 11

Co-authors: Paul Emery (24 shared papers)Philip Conaghan (21 shared papers)Richard Wakefield (15 shared papers)Andrew K. Brown (8 shared papers)Philip O’Connor (7 shared papers)Elizabeth M. A. Hensor (9 shared papers)Z Karim (4 shared papers)CHARLES G. PETERFY (3 shared papers)
Journals: Lara D. Veeken (9 papers)Environmental Entomology (8 papers)Annals of the Rheumatic Diseases (6 papers)The Lancet (4 papers)Arthritis Care & Research (3 papers)
Partner nations: United Kingdom United States Ireland

In The Last Decade

Mark A Quinn

94 papers receiving 5.2k citations

Mark A Quinn's Hit Papers

align trajectories log scale

An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis 2008 · 663 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2008 Arthritis & Rheumatism
2006 Arthritis & Rheumatism

Peers

Countries citing papers authored by Mark A Quinn

Since Specialization

Citations

This map shows the geographic impact of Mark A Quinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A Quinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A Quinn more than expected).

Fields of papers citing papers by Mark A Quinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A Quinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A Quinn. The network helps show where Mark A Quinn may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark A Quinn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark A Quinn Line = papers co-authored together Mark A Quinn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 97 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis Arthritis & Rheumatism ·Andrew K. Brown, Philip Conaghan, Z Karim, Mark A Quinn, Kei Ikeda, CHARLES G. PETERFY, Elizabeth M. A. Hensor, Richard Wakefield Hit paper breakdown →	2008	663
2	Presence of significant synovitis in rheumatoid arthritis patients with disease‐modifying antirheumatic drug–induced clinical remission: Evidence from an imaging study may explain structural progression Arthritis & Rheumatism ·Andrew K. Brown, Mark A Quinn, Z Karim, Philip Conaghan, CHARLES G. PETERFY, Elizabeth M. A. Hensor, Richard Wakefield, Philip O’Connor Hit paper breakdown →	2006	579
3	Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve‐month randomized, double‐blind, placebo‐controlled trial Arthritis & Rheumatism ·Mark A Quinn, Philip Conaghan, Philip O’Connor, Zunaid Karim, Adam S. Greenstein, Andrew K. Brown, Clare Brown, Alexander Duncan Fraser	2005	458
4	Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis Arthritis & Rheumatism ·Philip Conaghan, Philip O’Connor, Dennis G McGonagle, Paul Astin, Richard Wakefield, Wayne William Gibbon, Mark A Quinn, Zunaid Karim	2003	294
5	The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review Lara D. Veeken ·Sarah Westlake, Alexandra N. Colebatch, Janis Baird, Patrick D W Kiely, Mark A Quinn, Ernest Choy, A. J. Ostor, Chris J. Edwards	2009	294
6	Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: A comparison with arthroscopy and clinical examination Arthritis & Rheumatism ·Z Karim, Richard Wakefield, Mark A Quinn, Philip Conaghan, Andrew K. Brown, Douglas James Veale, P. O' Connor, Richard J. Reece	2004	190
7	Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review Lara D. Veeken ·Sarah Westlake, Alexandra N. Colebatch, Janis Baird, Nick P. Curzen, Patrick D W Kiely, Mark A Quinn, Ernest Choy, Andrew J.K. Östör	2010	180
8	Novel somatic mutations in UBA1 as a cause of VEXAS syndrome Blood ·James A. Poulter, Jason C. Collins, Catherine A. Cargo, Ruth Mary De Tute, PAUL A. S. EVANS, Daniela Ospina Cardona, David Bowen, Joanna R. Cunnington	2021	175
9	Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. PubMed ·Mark A Quinn, Paul Emery	2004	166
10	Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. PubMed ·Stephen J. Jarrett, Gaye Cunnane, Philip Conaghan, Sarah J. Bingham, Maya H Buch, Mark A Quinn, Paul Emery	2003	154
11	Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study Annals of the Rheumatic Diseases ·Benazir Saleem, Andrew K. Brown, Mark A Quinn, Zunaid Karim, Elizabeth M. A. Hensor, Philip Conaghan, CHARLES G. PETERFY, Richard Wakefield	2012	148
12	Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis Arthritis Care & Research ·Victoria Bejarano, Mark A Quinn, Philip Conaghan, Richard J. Reece, Anne‐Maree Keenan, David Walker, Andrew Gough, Michael Green	2008	148
13	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis Blood ·Frédérique Ponchel, Ann Wendy Morgan, Sarah J. Bingham, Mark A Quinn, Maya H Buch, Robert J. Verburg, Judy Henwood, Susan Douglas	2002	141
14	Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study) Annals of the Rheumatic Diseases ·Jackie L Nam, Édith Villeneuve, Elizabeth M. A. Hensor, Philip Conaghan, Helen Isobel Keen, Maya H Buch, Andrew Gough, M.J. Green	2013	137
15	The impact of ultrasonography on diagnosis and management of patients with musculoskeletal conditions Arthritis & Rheumatism ·Z Karim, Richard Wakefield, Philip Conaghan, Claire Alexandra Lawson, En Lin Goh, Mark A Quinn, Paul Astin, Philip O’Connor	2001	129
16	Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease‐modifying antirheumatic drugs: A clinical and imaging comparative study Arthritis & Rheumatism ·Benazir Saleem, Andrew K. Brown, Helen Isobel Keen, Sharmin Nizam, Jane E. Freeston, Zunaid Karim, Mark A Quinn, Richard Wakefield	2009	123
17	The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? British journal of rheumatology ·Mark A Quinn	2001	113
18	Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome Lara D. Veeken ·Mark A Quinn, Andrew Gough, M. J. Green, Josh Behan-Devlin, Elizabeth M. A. Hensor, Adam S. Greenstein, Abigail Fraser, Paul Emery	2005	111
19	Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol Arthritis & Rheumatism ·Mark A Quinn, Michael J. Green, Helena Marzo‐Ortega, Susanna Proudman, Zunaid Karim, Richard Wakefield, Philip Conaghan, Paul Emery	2003	87
20	Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study Annals of the Rheumatic Diseases ·Glenn Haugeberg, Philip Conaghan, Mark A Quinn, Paul Emery	2009	84

About Mark A Quinn

Mark A Quinn is a scholar working on Rheumatology, Insect Science, Hematology, Plant Science and Nature and Landscape Conservation, having authored 97 papers that have together received 5.5k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (33 papers), Systemic Lupus Erythematosus Research (14 papers), Insect-Plant Interactions and Control (11 papers), Autoimmune and Inflammatory Disorders Research (8 papers), Nematode management and characterization studies (7 papers), Legume Nitrogen Fixing Symbiosis (6 papers), Insect Pest Control Strategies (5 papers) and Ecology and Vegetation Dynamics Studies (5 papers). The work is most often cited by research in Rheumatology (3.9k citations), Hematology (734 citations), Genetics (285 citations), Immunology (565 citations) and Orthopedics and Sports Medicine (156 citations). Mark A Quinn has collaborated with scholars based in United Kingdom, United States and Ireland. Frequent co-authors include Paul Emery, Philip Conaghan, Richard Wakefield, Andrew K. Brown, Philip O’Connor, Elizabeth M. A. Hensor, Z Karim, CHARLES G. PETERFY, Zunaid Karim and Kei Ikeda. Their work appears in journals such as Lara D. Veeken, Environmental Entomology, Annals of the Rheumatic Diseases, The Lancet and Arthritis Care & Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark A Quinn

Impact in

Papers in i

In The Last Decade

Mark A Quinn

Mark A Quinn's Hit Papers

Peers

Countries citing papers authored by Mark A Quinn

Fields of papers citing papers by Mark A Quinn

All Works

About Mark A Quinn

Explore authors with similar magnitude of impact

Papers in